KRYS - Krystal Biotech - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KRYS is currently covered by 9 analysts with an average price target of $177.4. This is a potential upside of $46.01 (35.02%) from yesterday's end of day stock price of $131.39.

Krystal Biotech's activity chart (see below) currently has 60 price targets and 81 ratings on display. The stock rating distribution of KRYS is 92.86% BUY and 7.14% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 82.16% with an average time for these price targets to be met of 287.33 days.

Highest price target for KRYS is $240, Lowest price target is $189, average price target is $191.44.

Most recent stock forecast was given by GEULAH LIVSHITS from CHARDAN CAPITAL on 06-May-2025. First documented stock forecast 27-Jun-2018.

Currently out of the existing stock ratings of KRYS, 39 are a BUY (92.86%), 3 are a HOLD (7.14%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$219

$86.82 (65.68%)

$218

8 days ago
(06-May-2025)

7/11 (63.64%)

$82.2 (60.09%)

409

Buy

$189

$56.82 (42.99%)

$175

8 days ago
(06-May-2025)

4/5 (80%)

$52.2 (38.16%)

135

Buy

$240

$107.82 (81.57%)

$240

9 days ago
(05-May-2025)

24/34 (70.59%)

$100.53 (72.08%)

210

Buy

$215

$82.82 (62.66%)

2 months 25 days ago
(19-Feb-2025)

4/5 (80%)

$58.31 (37.21%)

139

Hold

$215

$82.82 (62.66%)

$206

2 months 25 days ago
(19-Feb-2025)

1/4 (25%)

$58.31 (37.21%)

135

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KRYS (Krystal Biotech) average time for price targets to be met?

On average it took 287.33 days on average for the stock forecasts to be realized with a an average price target met ratio 82.16

Which analyst has the current highest performing score on KRYS (Krystal Biotech) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on KRYS (Krystal Biotech)?

Josh Schimmer works at EVERCORE and has 3 price targets and 2 ratings on KRYS

Which analyst is the currently most bullish on KRYS (Krystal Biotech)?

Joseph Pantginis with highest potential upside - $107.82

Which analyst is the currently most reserved on KRYS (Krystal Biotech)?

Wangzhi Li with lowest potential downside - -$66

Krystal Biotech in the News

Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Krystal Biotech, Inc. (NASDAQ:KRYS) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology...

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Wall Street expects a year-over-year decline in earnings on lower revenues when Intellia Therapeutics, Inc. (NTLA) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company’s earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?